Table 3.

Other secondary efficacy outcomes at day 183

Ravulizumab (n = 96)Eculizumab (n = 95)
Total number of packed red blood cell units transfused, mean (SD)4.3 (4.76)3.4 (3.01)
Patients with major adverse vascular events, n (%)0 (0)0 (0)
Baseline*Day 183Baseline*Day 183
Clinical manifestations of PNH, n (%)
 Fatigue29 (30.2)42 (43.8)38 (40)36 (37.9)
 Abdominal pain5 (5.2)5 (5.2)6 (6.3)12 (12.6)
 Dyspnea6 (6.3)6 (6.3)10 (10.5)17 (17.9)
 Dysphagia2 (2.1)5 (5.2)2 (2.1)5 (5.2)
 Chest pain0 (0)2 (2.1)1 (1.1)5 (5.2)
 Hemoglobinuria4 (4.2)8 (8.3)7 (7.4)9 (9.5)
 Erectile dysfunction§5 (10.0)6 (12.0)7 (14.6)6 (12.5)
  • * Baseline was defined as the last nonmissing value before the first dose of study drug.

  • n = 97.

  • n = 98.

  • § n = 50 male patients in the ravulizumab group and n = 48 male patients in the eculizumab group.